MRC1 and neoplasm: Many Lynch syndrome-associated tumours also manifest loss of staining of the protein encoded by whichever MMR gene is mutated, making immunohistochemistry (IHC) of tumours (often together with microsatellite analysis) a helpful first step in the evaluation of a possible MMR-deficient tumour.